Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Soquelitinib - Corvus Pharmaceuticals

Next Previous
X
Search
Drug Profile

Soquelitinib - Corvus Pharmaceuticals

Alternative Names: CPI-818

Latest Information Update: 21 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corvus Pharmaceuticals
  • Developer Angel Pharmaceuticals; Corvus Pharmaceuticals
  • Class 1 ring heterocyclic compounds; Amides; Anti-inflammatories; Antiallergics; Antineoplastics; Antiretrovirals; Antivirals; Benzene derivatives; Cyclopropanes; Ethers; Ketones; Small molecules; Sulfides; Thiazoles
  • Mechanism of Action Emt protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T-cell lymphoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Anaplastic large cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma
  • Phase II T-cell lymphoma
  • Phase I Atopic dermatitis; T-cell leukaemia
  • Preclinical Autoimmune disorders; Graft-versus-host disease; HIV infections; Hypersensitivity; Inflammation; Lymphoproliferative disorders; Solid tumours; Systemic scleroderma

Most Recent Events

  • 14 Nov 2024 Preclinical trials in Systemic scleroderma in USA (PO)
  • 14 Nov 2024 Pharmacodynamics data from a preclinical trial in Systemic scleroderma released by Corvus Pharmaceuticals
  • 10 Sep 2024 Phase-III clinical trials in Anaplastic large cell lymphoma (Second-line therapy or greater) in South Korea, Australia, Canada, USA (PO) (NCT06561048)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top